Literature DB >> 26294290

New Delhi metallo-β-lactamase and OXA-48 carbapenemases in Gram-negative bacilli isolates in Libya.

Abdulmajeed G Kraiem1, Abdulaziz Zorgani2, Omar Elahmer3, Adnene Hammami4, Basma M Chaaben4, Khalifa Sifaw Ghenghesh5.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26294290      PMCID: PMC4543448          DOI: 10.3402/ljm.v10.29206

Source DB:  PubMed          Journal:  Libyan J Med        ISSN: 1819-6357            Impact factor:   1.743


× No keyword cloud information.
To the Editor Carbapenems (i.e. ertapenem, imipenem, meropenem, and doripenem) are second line antimicrobials reserved to treat serious infections, including those caused by Gram-negative bacilli (GNB) producing extended-spectrum β-lactamses (ESBLs). ESBLs mediate resistance among GNB to β-lactam drugs, including third generation cephalosporins. Emergence of carbapenemases-producing GNB (mainly Acinetobacter baumanii, Pseudomonas aeruginosa, and members of the family Enterobacteriaceae) in the last decade is a serious health problem globally. Carbapenemases are members of three molecular groups of β-lactamases, Ambler class A, B (i.e. metallo β-lactamases [MBLs]), and D (i.e. oxacillinases) (1, 2). Recently, the novel carbapenemase New Delhi MBL (NDM) was reported for the first time in Tunisia in Klebsiella pneumoniae isolated from a female patient transferred from Libya (3). However, there is little information regarding genes associated with carbapenem resistance among GNB in Libya. Included in the study were eight GNB isolates that are resistant to at least one carbapenem (i.e. ertapenem) obtained in 2013 and 2014 from different clinical specimens from patients at the time an infection occurred. Patients were aged between 10 and 87 years (mean=37.1 years). Information about patients and the organisms isolated from them included in the study are shown in Table 1. In this prospective investigation, clinical specimens were collected under approved ethical standards, and the study was reviewed and approved by the Academy of Graduate Studies, Tripoli, Libya.
Table 1

Information about patients and their isolated organisms

PatientGenderAge (years)Hospital/departmentHospital admissionSpecimenOrganism isolated
1Male30TMC/ICUInpatientEndotracheal tube tipAcinetobacter baumannii
2Female57TMC/GSICUInpatientSuction tip Acinetobacter baumannii
3Female46TMC/ICUInpatientSputum Pseudomonas aeruginosa
4Male25BPSH/ICUInpatientWound swab Pseudomonas putida
5Male10BPSHOutpatientWound swab Escherichia coli
6Male87TMCOutpatientEar swab Klebsiella pneumoniae
7Female42TMC/EndoInpatientBedsore swab Klebsiella pneumoniae
8Male30TMC/GSICUInpatientWound swab Enterobacter gergoviae

TMC=Tripoli Medical Center, BPSH=Burn and Pediatric Surgery Hospital, ICU=intensive care unit, GSICU=general surgical ICU, OP=outpatient, Endo=endocrinology.

TMC and BPSH are both located in Tripoli.

Information about patients and their isolated organisms TMC=Tripoli Medical Center, BPSH=Burn and Pediatric Surgery Hospital, ICU=intensive care unit, GSICU=general surgical ICU, OP=outpatient, Endo=endocrinology. TMC and BPSH are both located in Tripoli. All specimens were cultured on plates of blood agar and MacConkey agar (Oxoid Ltd., Basingstoke, Hampshire, UK) and incubated at 37°C for 24–48 h. Isolated organisms were identified to the species level and tested for their susceptibility to a variety of antimicrobial agents by the BD Phoenix Automated Microbiology System (PAMS, MSBD Biosciences, Sparks, MD, USA) as recommended by the manufacturer. PAMS provides antimicrobial susceptibility results as susceptible (S), intermediate susceptible (I), or resistant (R) and are interpreted according to Clinical and Laboratory Standards Institute criteria (4). Quality control strains used included Escherichia coli ATCC 25922, K. pneumoniae ATCC 700603, and P. aeruginosa ATCC 27853 (ATCC, LGC Standards S.r.l., Italy). Furthermore, six of the GNB isolates were tested phenotypically for the production of MBLs by the MIC Test Strip MBL (Liofilchem, Rosetodegli Abruzzi, Italy) as recommended by the manufacturer. All eight isolates were examined for genes encoding ESBLs blaCTX-M, blaGES, blaVEB, blaPER, or blaBES and carbapenemases blaKPC, blaVIM, blaNDM, or blaOXA-48 by polymerase chain reaction (PCR) using primers and conditions described previously (5, 6). In addition, both A. baumanii isolates were further tested for carbapenemase genes blaOXA-23-like, blaOXA-24/40-like, blaOXA-143-like, blaOXA-51-like, and blaOXA-58-like using PCR as above. All A. baumanii and Pseudomonas sp. isolates were resistant to the three carbapenems as well as to nearly all other antimicrobials that were used. Only colisitin showed excellent activity against the GNB isolates investigated (100% susceptible) followed by amikacin (50% susceptible). Furthermore, all organisms were multidrug resistant (MDR; resistance to three or more antimicrobial groups). Table 2 shows the antimicrobial susceptibility of the investigated GNB isolates.
Table 2

Antimicrobial susceptibility and metallo-β-lactamases of Gram-negative bacilli isolates from different clinical specimens in Tripoli, Libya

Antimicrobial agent

No.OrganismAMCNEPIPMPCXCRCTCZCPANPTTSCFLFCLMBLs
1 Acinetobacter baumannii RRRRRRRRRRRRRRRS+
2 Acinetobacter baumannii RRRRRRRRRRRRSRRSND
3 Pseudomonas aeruginosa RRRRRRRRIIISRRRS+
4 Pseudomonas putida RRRRRRRRRRRRRSSS+
5 Escherichia coli SRRSSRRRSRRSRRRS
6 Klebsiella pneumoniae SSRRRRRRRRRRRRRS+
7 Klebsiella pneumoniae SRRIRRRRRRRRSRRS
8 Enterobacter gergoviae SRRSRRRRRRRRSRRSND

AK=amikacin, CN=gentamicin, EP=ertapenem, IP=imipenem, MP=meropenem, CX=cefoxitin, CR=cefuroxime, CT=ceftriaxone, CZ=ceftazidime, CP=cefepime, AN=aztronam, PT=pipracillin-tazobactam, TS=trimethoprim-sulfamethoxazole, CF=ciprofloxacin, LF=levofloxacin, CL=colisitin. S=susceptible, I=intermediate susceptible, R=resistant, MTLs=metallo β-lactamases tested phenotypically, += positive, −=negative, ND=not done.

Antimicrobial susceptibility and metallo-β-lactamases of Gram-negative bacilli isolates from different clinical specimens in Tripoli, Libya AK=amikacin, CN=gentamicin, EP=ertapenem, IP=imipenem, MP=meropenem, CX=cefoxitin, CR=cefuroxime, CT=ceftriaxone, CZ=ceftazidime, CP=cefepime, AN=aztronam, PT=pipracillin-tazobactam, TS=trimethoprim-sulfamethoxazole, CF=ciprofloxacin, LF=levofloxacin, CL=colisitin. S=susceptible, I=intermediate susceptible, R=resistant, MTLs=metallo β-lactamases tested phenotypically, += positive, −=negative, ND=not done. Of the ESBLs genes examined, blaCTX-M was detected in one K. pneumoniae and in the Enterobacter gergoviae isolate, and blaGES in the P. aeruginosa isolate. Other ESBL genes examined were not detected in all eight GNB isolates. Of the carbapenemase genes investigated, blaNDM was detected in one K. pneumoniae, and blaOXA-48 in E. gergoviae and in another K. pneumoniae isolate. On the other hand, the carbapenemase gene blaKPC was not detected in all isolates investigated. Table 3 shows genes encoding ESBLs and carbapenemases in the GNB isolates from Tripoli, Libya.
Table 3

Genes encoding extended-spectrum β-lactamases (ESBLs) and carbapenemases in Gram-negative bacilli from Tripoli, Libya

ESBLs genesaCarbapenemase genesa,b


No.OrganismblaCTX-M bla GES bla NDM bla VIM bla OXA-48 bla OXA-23-like bla OXA-51-like
1 Acinetobacter baumannii NNNNNPP
2 Acinetobacter baumannii NNNNNPP
3 Pseudomonas aeruginosa NPNNNNDND
4 Pseudomonas putida NNNPNNDND
5 Escherichia coli NNNNNNDND
6 Klebsiella pneumoniae PNPNNNDND
7 Klebsiella pneumoniae NNNNPNDND
8 Enterobacter gergoviae PNNNPNDND

ESBLs genes blaVEB, blaPER and blaBES and carbapenemase gene blaKPC were not detected in all eight isolates tested.

Carbapenemases genes blaOXA-24/40-like, blaOXA-58-like and blaOXA-143 were not detected in both A. baumanii isolates examined.

N=negative, P=positive, ND=not done.

Genes encoding extended-spectrum β-lactamases (ESBLs) and carbapenemases in Gram-negative bacilli from Tripoli, Libya ESBLs genes blaVEB, blaPER and blaBES and carbapenemase gene blaKPC were not detected in all eight isolates tested. Carbapenemases genes blaOXA-24/40-like, blaOXA-58-like and blaOXA-143 were not detected in both A. baumanii isolates examined. N=negative, P=positive, ND=not done. Oxacillinases are mainly present in Acinetobacter sp. (7), and some of them are intrinsic to the organism (e.g. OXA-51) while others are acquired (e.g. OXA-23). bla OXA-23-like and bla OXA-51-like were found in both A. baumanii isolates. Recently, Mathlouthi et al. (8) reported MDR A. baumannii isolates harboring bla OXA-23-like, bla OXA-24-like, and bla OXA-48-like genes in Libya. On the other hand, we identified OXA-48 in one K. pneumoniae as well as in the E. gergoviae isolate. Kocsis et al. (9) reported K. pneumoniae harboring OXA-48 carbapenemase in a Libyan refugee in Italy. In addition, several studies reported OXA-48 carbapenemase-producing K. pneumoniae in patients transferred from Libya to neighboring and European countries (e.g. Tunisia, Denmark, and Slovenia) (3, 10–12). However, there are no reports of bla OXA-48-positive K. pneumonia and E. gergoviae from Libya. Both bla CTX-M and bla NDM were detected in Klebsiella pneumoniae isolated from an ear swab from a female outpatient with an ear infection. This isolate was also positive for MBLs by the phenotypic method used (Table 2). K. pneumoniae harboring bla NDM has not been reported from Libya in the past. Genes coding for the ESBLs and carbapenemases tested were not detected in the E. coli isolate. However, the organism was ESBL-positive phenotypically (data not shown), which may suggest that other ESBLs not investigated in this work might be responsible for its resistance to the third generation cephalosporin. In conclusion, to the authors’ knowledge this is the first report from Libya of K. pneumoniae harboring bla NDM and bla CTX-M, K. pneumoniae harboring bla OXA-48, and E. gergoviae harboring bla OXA-48 and bla CTX-M. Emergence of MDR GNB harboring genes coding for carbapenemases will undoubtedly limit the use of carbapenems in treating serious infectious in the country and also in the nearby countries.
  11 in total

Review 1.  OXA-type carbapenemases.

Authors:  Jan Walther-Rasmussen; Niels Høiby
Journal:  J Antimicrob Chemother       Date:  2006-01-30       Impact factor: 5.790

2.  Emergence of NDM-1 in association with OXA-48 in Klebsiella pneumoniae from Tunisia.

Authors:  Adam Ben Nasr; Dominique Decré; Fabrice Compain; Nathalie Genel; Farouk Barguellil; Guillaume Arlet
Journal:  Antimicrob Agents Chemother       Date:  2013-06-10       Impact factor: 5.191

3.  Patients transferred from Libya to Denmark carried OXA-48-producing Klebsiella pneumoniae, NDM-1-producing Acinetobacter baumannii and meticillin-resistant Staphylococcus aureus.

Authors:  Anette M Hammerum; Anders R Larsen; Frank Hansen; Ulrik S Justesen; Alice Friis-Møller; Lars E Lemming; Kurt Fuursted; Pia Littauer; Kristian Schønning; Bente Gahrn-Hansen; Svend Ellermann-Eriksen; Brian Kristensen
Journal:  Int J Antimicrob Agents       Date:  2012-06-27       Impact factor: 5.283

4.  Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae.

Authors:  Caroline Dallenne; Anaelle Da Costa; Dominique Decré; Christine Favier; Guillaume Arlet
Journal:  J Antimicrob Chemother       Date:  2010-01-12       Impact factor: 5.790

5.  Klebsiella pneumoniae harbouring OXA-48 carbapenemase in a Libyan refugee in Italy.

Authors:  E Kocsis; C Savio; M Piccoli; G Cornaglia; A Mazzariol
Journal:  Clin Microbiol Infect       Date:  2013-05-09       Impact factor: 8.067

Review 6.  Updated functional classification of beta-lactamases.

Authors:  Karen Bush; George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

7.  OXA-48 carbapenemase-producing Klebsiella pneumoniae isolated from Libyan patients.

Authors:  Emilie Lafeuille; Dominique Decré; Farah Mahjoub-Messai; Philippe Bidet; Guillaume Arlet; Edouard Bingen
Journal:  Microb Drug Resist       Date:  2013-06-29       Impact factor: 3.431

8.  Emergence of Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Clinical Isolates Collected from Some Libyan Hospitals.

Authors:  Najla Mathlouthi; Zaynab Areig; Charbel Al Bayssari; Sofiane Bakour; Allaaeddin Ali El Salabi; Salha Ben Gwierif; Abdulaziz A Zorgani; Karim Ben Slama; Chedly Chouchani; Jean-Marc Rolain
Journal:  Microb Drug Resist       Date:  2015-01-14       Impact factor: 3.431

9.  The structure of beta-lactamases.

Authors:  R P Ambler
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1980-05-16       Impact factor: 6.237

10.  Spread of carbapenem-resistant Acinetobacter baumannii carrying a plasmid with two genes encoding OXA-72 carbapenemase in Lithuanian hospitals.

Authors:  Justas Povilonis; Vaida Seputiene; Renatas Krasauskas; Raminta Juskaite; Monika Miskinyte; Kestutis Suziedelis; Edita Suziedeliene
Journal:  J Antimicrob Chemother       Date:  2012-12-19       Impact factor: 5.790

View more
  3 in total

1.  First Report of German Cockroaches (Blattella germanica) as Reservoirs of CTX-M-15 Extended-Spectrum-β-Lactamase- and OXA-48 Carbapenemase-Producing Enterobacteriaceae in Batna University Hospital, Algeria.

Authors:  Lotfi Loucif; Djamila Gacemi-Kirane; Zineb Cherak; Naima Chamlal; Nadia Grainat; Jean-Marc Rolain
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 2.  Epidemiology of Carbapenem Resistant Klebsiella pneumoniae Infections in Mediterranean Countries.

Authors:  Corrado Girmenia; Alessandra Serrao; Martina Canichella
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-07-01       Impact factor: 2.576

3.  Current problematic and emergence of carbapenemase-producing bacteria: a brief report from a Libyan hospital.

Authors:  Asma Elramalli; Nariman Almshawt; Mohamed Omar Ahmed
Journal:  Pan Afr Med J       Date:  2017-03-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.